TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02655796

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OAK
Description: The OAK device evaluates the fall risk through exercises assessing mobility, equilibrium and postural reaction.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OAK
Description: The OAK device evaluates the fall risk through exercises assessing mobility, equilibrium and postural reaction.
Study: NCT01202201

Intervention type: OTHER
Intervention: Database analysis
Description: Review and collect data from database (electronic admission database or any other applicable database of the hospital)
Study: NCT04165551

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Volunteers will take 1 capsule a day of the Probiotic during lunch without any restrictions on diet or lifestyle.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Volunteers will take 1 capsule a day of the Placebo during lunch without any restrictions on diet or lifestyle.
Study: NCT03886922

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levcromakalim
Description: Intravenous infusion of levcromakalim or placebo for 20 minutes. To investigate the role of levcromakalim/placebo on cranial arteries in healthy volunteers after glibenclamide administration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levcromakalim
Description: Intravenous infusion of levcromakalim or placebo for 20 minutes. To investigate the role of levcromakalim/placebo on cranial arteries in healthy volunteers after glibenclamide administration.
Study: NCT03101189

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-541468
Description: Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-541468
Description: Capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Matching placebo capsule
Study: NCT02862444

Intervention type: OTHER
Intervention: Culturally Appropriate Intervention
Description: Women in the intervention arm will receive a culturally appropriate intervention that will be provided to them according to the five strategies of culturally appropriate interventions of Kreuter et al. (2003).
Study: NCT00036270

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exemestane (Aromasin)
Description: exemestane, orally, 25 mg, for 5 years

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tamoxifen + exemestane
Description: tamoxifen, 20 mg, orally, daily, 2-3 years; followed by exemestane, orally, 25 mg, for a total of 5 years of therapy
Study: NCT03036007

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Prescribed Physical Activity
Description: General physical activity prescribed by a physiotherapist

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercises with Internet support
Description: Neck-specific exercise with Internet support
Study: NCT03661671

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: LCI+white light
Description: Firstly use white light to observe from cardia to duodenum and then switch LCI model to observe from antrum to cardia
Study: NCT03886922

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: Intravenous infusion of levcromakalim or placebo for 20 minutes. To investigate the role of levcromakalim/placebo on cranial arteries in healthy volunteers after glibenclamide administration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: Intravenous infusion of levcromakalim or placebo for 20 minutes. To investigate the role of levcromakalim/placebo on cranial arteries in healthy volunteers after glibenclamide administration.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Saline
Description: Intravenous infusion of levcromakalim or placebo for 20 minutes. To investigate the role of levcromakalim/placebo on cranial arteries in healthy volunteers after glibenclamide administration.
Study: NCT01789658

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Description: Cryotherapy with ice-chips, ice cream or ice water is given during conditioning treatment with chemotherapy prior to HSCT.
Study: NCT04397692

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nitric Oxide delivered via LungFit™ system
Description: Patients will receive inhalations of 80 ppm for 40 min 4 times a day
Study: NCT04113109

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Para-aminohippurate
Description: Para-aminohippurate (PAH) will be given at a dose of 8 mg/kg loading dose followed by a 12 mg/min steady-state infusion during each study day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Para-aminohippurate
Description: Para-aminohippurate (PAH) will be given at a dose of 8 mg/kg loading dose followed by a 12 mg/min steady-state infusion during each study day.
Study: NCT04021446

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: personalized exercise prescription
Study: NCT03529929

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: 6 day dosing as dictated by Medrol 6 Day Dose Pack
Study: NCT01349972

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alvocidib
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: daunorubicin hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mitoxantrone hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cytarabine
Description: Given IV
Study: NCT01369225

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AAB-003 (PF-05236812)
Description: 0.5 mg/kg AAB-003, IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AAB-003 (PF-05236812)
Description: 1 mg/kg AAB-003, IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AAB-003 (PF-05236812)
Description: 2 mg/kg AAB-003, IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AAB-003 (PF-05236812)
Description: 4 mg/kg AAB-003, IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AAB-003 (PF-05236812)
Description: 8 mg/kg AAB-003, IV
Study: NCT03043807

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide Acetate
Description: 22.5mg by intramuscular (IM) injection every 3 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75 mg/m2 IV will be given on day 1 every 3 weeks, up to 6 cycles. Dose may decreased in the following intervals: 65 mg/M2, 55 mg/M2, 35 mg/M2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bicalutamide
Description: bicalutamide (Casodex) 50mg by mouth daily

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Radiation will be delivered in 1 to 5 fractions, and the dose and fractionation schedule will depend on the size and location of the lesion and the surrounding normal tissue constraints in accordance with AAPM Task Group 101 recommendations. Typical doses include 16 - 24 Gy in 1 fraction, 48 - 50 Gy in 4 fractions, and 50 - 60 Gy in 5 fractions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Acetate
Description: Abiraterone acetate 1000 mg / day may be given at the investigator's discretion.
Study: NCT00105183

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo infusion, single

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: EZ-2053
Description: single IV infusion, 9 mg/kg

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: EZ-2053 5mg/kg
Description: single IV infusion, 5mg/kg
Study: NCT03970707

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Small Number of Players training protocol A
Description: 8 participants each side game (4vs4), size of pitch area 25\*20 m. In total, 6 consecutive 4-minutes bouts interspersed by a 3-minutes rest between each bout will be executed.
Study: NCT04113109

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Para-aminohippurate
Description: Para-aminohippurate (PAH) will be given at a dose of 8 mg/kg loading dose followed by a 12 mg/min steady-state infusion during each study day.
Study: NCT03970707

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Large Number of Players training protocol B
Description: 16 participants each side game (8vs8), size of pitch area 25\*20 m. In total, 3 consecutive 8-minutes bouts interspersed by a 1-minutes rest between each bout will be executed.
Study: NCT01999023

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low protein formula group
Description: Low protein formula formula (28.5 g) twice a day
Study: NCT03145597

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laminate veneer of composite
Description: Composite laminate veneers, 2-4-6 veneers per patient

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laminate veneer of ceramic
Description: laminate of ceramic (Empress Esthetic, Ivoclar Vivadent), ceramic laminate veneer, 2-4-6 veneers per patient will be made.
Study: NCT01855113

Intervention type: DEVICE
Intervention: Invisalign
Study: NCT02096042

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin
Description: Pilot Phase: Starting dose of Brentuximab Vedotin 1.2 mg/kg intravenous (IV) infusion over approximately 30 minutes on days 1, 8, and 15 of each 28-day cycle.~Phase I Dose-Escalation Phase: Starting dose of Brentuximab Vedotin 1.0 mg/kg IV (starting dose level 1), or one-dose level lower than the established MTD if the pilot portion of the study establishes a lower MTD, infusion over approximately 30 minutes on days 1, 8, and 15 of each 28-day cycle.~Phase II Dose-Expansion Phase: Patients receive Brentuximab Vedotin at MTD from dose-escalation phase by vein on Days 1, 8, and 15 of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin
Description: Pilot Phase: Starting dose of Brentuximab Vedotin 1.2 mg/kg intravenous (IV) infusion over approximately 30 minutes on days 1, 8, and 15 of each 28-day cycle.~Phase I Dose-Escalation Phase: Starting dose of Brentuximab Vedotin 1.0 mg/kg IV (starting dose level 1), or one-dose level lower than the established MTD if the pilot portion of the study establishes a lower MTD, infusion over approximately 30 minutes on days 1, 8, and 15 of each 28-day cycle.~Phase II Dose-Expansion Phase: Patients receive Brentuximab Vedotin at MTD from dose-escalation phase by vein on Days 1, 8, and 15 of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Azacytidine
Description: Phase I Dose-Escalation Phase and Phase II Dose-Expansion Phase: 5-Azacytidine at 75 mg/m2/day by vein or subcutaneously on days 1-7 every 28 days.
Study: NCT02109419

Intervention type: OTHER
Intervention: HHT-G
Description: Helping Hands Technology global cognitive function assessment
Study: NCT03054740

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gebauer Ethyl Chloride
Description: Will be administered according to manufacturers recommendations which is to spray the aerosol can for 4-10 seconds from a distance of 3 to 9 inches. Do not spray longer than 10 seconds.
Study: NCT04113109

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iohexol
Description: Iohexol will be given as 5 mL of iohexol solution (3.235 g iohexol) intravenously on each study day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iohexol
Description: Iohexol will be given as 5 mL of iohexol solution (3.235 g iohexol) intravenously on each study day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iohexol
Description: Iohexol will be given as 5 mL of iohexol solution (3.235 g iohexol) intravenously on each study day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iohexol
Description: Iohexol will be given as 5 mL of iohexol solution (3.235 g iohexol) intravenously on each study day.
Study: NCT00927602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fondaparinux
Description: once daily sc injection, 1,5 mg, max 14 days
Study: NCT03217630

Intervention type: OTHER
Intervention: Fasting 2 h after clear liquid or 6h after a light meal
Description: The fasting time for all patients is 2 h after clear liquid or 6h after a light meal, then gastric ultrasound examination is performed.

Intervention type: OTHER
Intervention: Fasting 2 h after clear liquid or 6h after a light meal
Description: The fasting time for all patients is 2 h after clear liquid or 6h after a light meal, then gastric ultrasound examination is performed.
Study: NCT03054740

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nature's Tears
Description: Sterile water mist will be administered 1-2 sprays prior to intravenous access
Study: NCT01210755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban, Dabigatran
Description: Rivaroxaban: One dose of 20mg (2 tablets of 10mg) then Dabigatran: One dose of 150mg(2 capsules of 75mg) two weeks later
Study: NCT04590222

Intervention type: OTHER
Intervention: blood sample
Description: One blood sample of 60 mL (EDTA)

Intervention type: OTHER
Intervention: blood sample
Description: One blood sample of 60 mL (EDTA)

Intervention type: OTHER
Intervention: blood sample
Description: One blood sample of 60 mL (EDTA)

Intervention type: OTHER
Intervention: blood sample
Description: One blood sample of 60 mL (EDTA)
Study: NCT04649021

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intramuscular injection
Study: NCT01450228

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KI1001
Description: Prolonged release melatonin 2mg
Study: NCT04363242

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SYN125
Description: Administered by IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SYN125
Description: Administered by IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SYN004
Description: Administered by IV infusion
Study: NCT01450228

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo KI1001
Description: Placebo KI1001 tablets
Study: NCT00089544

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacarbazine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Given subcutaneously
Study: NCT02109419

Intervention type: OTHER
Intervention: HHT-D
Description: Helping Hands Technology depression assessment

Intervention type: OTHER
Intervention: Geriatric Depression Scale (DGS)
Description: Geriatric Depression Scale (DGS)

Intervention type: OTHER
Intervention: MMSE
Description: Mini Mental State Exam
Study: NCT02352779

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 Fatty Acid
Description: Given PO
Study: NCT01456130

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alogliptin
Description: Alogliptin tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapid-acting insulin secretagogue
Description: Either of the following commercially available rapid-acting insulin secretagogues as prescribed by the Investigator: (i) Nateglinide: Dose: 30 mg tablet or 90 mg tablet (ii) Mitiglinide calcium hydrate: Dose: 5 mg tablet or 10 mg tablet
Study: NCT03882593

Intervention type: PROCEDURE
Intervention: Analysis of arterial filters after CPB
Description: At the end of surgery, the arterial filter is withdrawn from cardiopulmonary bypass circuit to be prepared and analysed by SEM.
Study: NCT02352779

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 Fatty Acid
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Given PO

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT00089544

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT04590222

Intervention type: OTHER
Intervention: blood sample
Description: One blood sample of 60 mL (EDTA)
Study: NCT00089544

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: Given orally

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgical resection
Study: NCT00807183

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: woodstove
Description: installation of new EPA-certified woodstove
Study: NCT00089544

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgical resection
Study: NCT02262468

Intervention type: RADIATION
Intervention: x ray
Study: NCT02582736

Intervention type: DRUG
Intervention: Olanzapine
Description: Exposure to olanzapine (ATC N05AH03) will be defined as a prescription for olanzapine on the date of cohort entry.

Intervention type: DRUG
Intervention: Risperidone
Description: Exposure to risperidone (ATC N05AX08) will be defined will be defined as a prescription for risperidone on the date of cohort entry.

Intervention type: DRUG
Intervention: atypical antipsychotics (other)
Description: Exposure to other atypitical antipsychotics (ATC N05AH02, N05AH04, N05AE04, N05AX13, N05AX12) will be defined will be defined as a prescription for an atypical antipsychotic other than olanzapine on the date of cohort entry.

Intervention type: DRUG
Intervention: typical antipsychotics
Description: Exposure to typical antipsychotics (M03BB02, N05AA01, N05AF03, N05AF01, N05AB02, N05AG01, N05AD01, N05AA02, N05AH01, N05AC03, N05AB03, N05AG02, N05AC04, N07XX06, N05AB05, N05AB08, N05AC02, N05AF04, N05AB06, N05AF05) will be defined as a prescription for a typical antipsychotic on the date of cohort entry.
Study: NCT00459212

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GTI-2040
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative study

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative study
Study: NCT01210755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran; Rivaroxaban
Description: Dabigatran: One dose of 150mg(2 capsules of 75mg) then Rivaroxaban: One dose of 20mg (2 tablets of 10mg)two weeks later
Study: NCT00623285

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: Pregabalin 150mg orally 60 minutes pre-operatively. Patients will receive the first dose post-operatively 12 hours after the initial dose was taken (+ 6 hours) given that patient is able to swallow and then they will receive 150mg twice a day through the first 2 post-operative days for a total of six doses.
Study: NCT00807183

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: inactive air filter
Description: air filter units without filter in place

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active air filter
Description: air filter units correctly operating
Study: NCT02589197

Intervention type: DEVICE
Intervention: Group 1 (Medial-Pivot)
Description: EVOLUTION® Total Knee Arthroplasty Medial Pivot system with CS inserts
Study: NCT03345901

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemafibrate
Description: 0.2 mg orally BID - twice daily
Study: NCT00623285

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo/Lactose
Description: Matching Placebo orally,60 minutes pre-operatively. Patients will receive the first dose post-operatively 12 hours after the initial dose was taken (+ 6 hours) given that patient is able to swallow and then they will receive placebo twice a day through the first 2 post-operative days for a total of six doses. If the patient is unable to swallow and NG tube is in place, the medication can be dissolved in water and administered through the NG tube.
Study: NCT03504462

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Specific block of medial and lateral plantar nerves
Description: Specific injection of long duration local anesthetic in contact with medial and lateral plantar nerves.~Local anesthetic : Ropivacaine : 0,375% - 5 ml per nerve.
Study: NCT02708615

Intervention type: OTHER
Group type: OTHER
Intervention: Type of speculum vaginal insertion method
Description: Speculum insertion type will either be vertical rotation (as per common practice in Canada) or straight horizontal insertion

Intervention type: OTHER
Group type: OTHER
Intervention: Type of speculum vaginal insertion method
Description: Speculum insertion type will either be vertical rotation (as per common practice in Canada) or straight horizontal insertion
Study: NCT04444492

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab Injection
Description: initial three injections of Ranibizumab - afterwards pro re nata monthly

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab Injection
Description: initial three injections of Ranibizumab - afterwards pro re nata monthly

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser photocoagulation
Description: Areas of capillary non-perfusion will be treated with photocoagulation upto 4 times
Study: NCT02811796

Intervention type: OTHER
Intervention: angio-based FFR estimation
Description: The investigators will acquire specific angiograms to permit angio-based FFR (QFR) calculation. An independent corelab will estimate the QFR value. This value will be related to prognosis to verify if it is able to discriminate those at higher risk of adverse events.
Study: NCT01189799

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational therapy
Description: Twelve, 60 minute weekly structured manualized therapy sessions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dual Recovery Anonymous/Tx as usual
Description: Twelve 60 minute weekly sessions of peer led 12-step Dual Recovery Anonymous group.